Literature DB >> 20425456

Late complications after treatment for Hodgkin lymphoma.

Andrea K Ng1.   

Abstract

Long-term survivors of Hodgkin lymphoma face a number of late effects that can significantly affect the length and quality of their life. These include increased risk of second malignancy, cardiovascular disease, pulmonary dysfunction, infections, and endocrinopathy. Of these late effects, second malignancies and cardiac disease are the two leading contributors to the excess mortality seen in long-term Hodgkin lymphoma survivors. An improved understanding of the range of late complications after Hodgkin lymphoma therapy and the identification of treatment-related and patient-related risk factors can guide the development of screening and prevention programs for long-term survivors who have completed treatment. In addition, increasing recognition of late complications has in part led to substantial changes in the treatment of Hodgkin lymphoma over the years. Continued long-term follow-up of patients treated with modern therapy and documentation of late effects associated with newer treatment will be essential.

Entities:  

Mesh:

Year:  2008        PMID: 20425456     DOI: 10.1007/s11899-008-0018-6

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  38 in total

1.  Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment.

Authors:  A J Swerdlow; M J Schoemaker; R Allerton; A Horwich; J A Barber; D Cunningham; T A Lister; A Z Rohatiner; G Vaughan Hudson; M V Williams; D C Linch
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

2.  Report from the Rockefellar Foundation Sponsored International Workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy.

Authors:  Peter Mauch; Andrea Ng; Berthe Aleman; Patrice Carde; Louis Constine; Volker Diehl; Ketayun Dinshaw; Mary Gospodarowicz; Steve Hancock; David Hodgson; Richard Hoppe; Raymond Liang; Markus Loeffler; Lena Specht; Lois B Travis; Andrew Wirth; Joachim Yahalom
Journal:  Eur J Haematol Suppl       Date:  2005-07

3.  Late cardiac toxicity secondary to treatment in Hodgkin's disease. A study comparing doxorubicin, epirubicin and mitoxantrone in combined therapy.

Authors:  Agustin Avilés; Natividad Neri; Jesús M Nambo; Judith Huerta-Guzman; Alejandra Talavera; Sergio Cleto
Journal:  Leuk Lymphoma       Date:  2005-07

4.  Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.

Authors:  F E van Leeuwen; A M Chorus; A W van den Belt-Dusebout; A Hagenbeek; R Noyon; E H van Kerkhoff; H M Pinedo; R Somers
Journal:  J Clin Oncol       Date:  1994-05       Impact factor: 44.544

5.  Cardiac lesions after mediastinal irradiation for Hodgkin's disease.

Authors:  C Glanzmann; P Huguenin; U M Lütolf; R Maire; R Jenni; V Gumppenberg
Journal:  Radiother Oncol       Date:  1994-01       Impact factor: 6.280

6.  Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy.

Authors:  David C Hodgson; Melania Pintilie; Leah Gitterman; Beth Dewitt; Carol-Ann Buckley; Sameera Ahmed; Katherine Smith; Amanda Schwartz; Richard W Tsang; Michael Crump; Woodrow Wells; Alexander Sun; Mary K Gospodarowicz
Journal:  Hematol Oncol       Date:  2007-03       Impact factor: 5.271

7.  Asymptomatic cardiac disease following mediastinal irradiation.

Authors:  Paul A Heidenreich; Steven L Hancock; Byron K Lee; Carol S Mariscal; Ingela Schnittger
Journal:  J Am Coll Cardiol       Date:  2003-08-20       Impact factor: 24.094

8.  Coronary artery disease mortality in patients treated for Hodgkin's disease.

Authors:  J F Boivin; G B Hutchison; J H Lubin; P Mauch
Journal:  Cancer       Date:  1992-03-01       Impact factor: 6.860

9.  Exercise reduces fatigue in chronic fatigued Hodgkins disease survivors--results from a pilot study.

Authors:  L M Oldervoll; S Kaasa; H Knobel; J H Loge
Journal:  Eur J Cancer       Date:  2003-01       Impact factor: 9.162

10.  Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

Authors:  Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans-Konrad Müller-Hermelink; Eckhardt Dühmke; Markus Loeffler
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

View more
  1 in total

1.  Long-term risk of cardiovascular mortality in lymphoma survivors: A systematic review and meta-analysis.

Authors:  Devon J Boyne; Alexis T Mickle; Darren R Brenner; Christine M Friedenreich; Winson Y Cheung; Karen L Tang; Todd A Wilson; Diane L Lorenzetti; Matthew T James; Paul E Ronksley; Doreen M Rabi
Journal:  Cancer Med       Date:  2018-08-15       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.